Unum Therapeutics Inc. (UMRX)
(Delayed Data from NSDQ)
$3.35 USD
+0.07 (2.13%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.35 USD
+0.07 (2.13%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (UMRX) Outperforming Other Medical Stocks This Year?
Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (UMRX) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics
Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside
by Sweta Killa
On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q2 revenues increase year over year.
Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.
Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Is Unum Therapeutics (UMRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (UMRX) Outperforming Other Medical Stocks This Year?
Unum Therapeutics Inc. (UMRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.
Dynavax Signs a Pact to Develop Universal Influenza Vaccine
by Zacks Equity Research
Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.
Top Ranked Momentum Stocks to Buy for July 17th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
Top Ranked Momentum Stocks to Buy for July 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th
Unum Therapeutics Inc. (UMRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).
Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
by Zacks Equity Research
During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.
Unum Therapeutics Inc. (UMRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unum Therapeutics Inc. (UMRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?